Virtual UW-Madison/MCW Primary Central Nervous System Malignancy Symposium

March 20, 2021

The goal of this educational activity is to present a multidisciplinary approach to the clinical management of primary glioma. After attending, the participant will be able to discuss available, innovative clinical trial options and ideas for future clinical trials and also provide the latest updates on current treatment trends in neurosurgery, radiation oncology, and neuro-oncology. 

Practice Gaps and Needs

This interprofessional primary glioma update will be a premier inaugural educational event in Wisconsin designed to educate the broader oncology community involved with caring for patients with primary glioma. This course will discuss current standard of interprofessional care management for patients with glioma as well as highlight advances in technology and medical care focused on improved outcomes and quality of life for patients with glioma. 

Elements of Competence

This CE activity has been designed to improve learner competence and focuses on the American Board of Medical Specialties' areas of patient care and procedural skills, medical knowledge, and interpersonal and communication skills.

This activity also focuses on the interprofessional competencies of values/ethics for interprofessional practice, roles/responsibilities, interprofessional communication, and teams/teamwork.

Target Audience

This activity is designed to educate medical oncologists, radiation oncologists, neurologists, neuropsychiatrists, neurosurgeons, pathologists, radiation oncologists, surgical oncologists, neuro-oncologists, advanced practice nurses, PAs, RNs and other healthcare providers on the clinical management of primary glioma.

Learning Objectives

At the conclusion of this CE activity, members of the health care team will be able to:

  • Describe new neurosurgical advances and techniques in the management of primary glioma.
  • Report updates in the fields of radiation oncology and medical oncology in the management of patients with primary glioma.
  • List all the clinical trials related to primary glioma.

Jointly Provided by

University of Wisconsin School of Medicine and Public Health
   Department of Neurological Surgery
   University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)
The Medical College of Wisconsin

 

 

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit
  • 7.75 ANCC Contact Hours
  • 7.75 University of Wisconsin–Madison Continuing Education Hours
    • 7.75 Approved for AMA PRA Category 1 Credit™
Registration opens: 
02/18/2021
Course expires: 
12/31/2021
Event starts: 
03/20/2021 - 7:45am
Event ends: 
03/20/2021 - 5:00pm
Cost:
$50.00
Rating: 
0

Saturday, March 20, 2021

 

7:45 AM

Welcome
Robert Dempsey, MD
Co-Directors: Mahua Dey, MD and Joseph Bovi, MD

Clinical Management: Malignant Glioma
Moderators:  Mahua Dey, MD and Joseph Bovi, MD

8:00 AM

Malignant Glioma Update
Roger Stupp, MD

8:40 AM

Applying Immunotherapy during Surgical Clinical Trials for GBM
E. Antonio Chiocca, MD, PhD

9:20 AM

Radiation Management of High Grade Glioma
Minesh Mehta, MD

10:00 AM

Panel Discussion

10:15 AM

BREAK

Clinical Management: Low Grade Glioma
Moderators:  Mahua Dey, MD and Joseph Bovi, MD

10:30 AM

The Evolution of How We Diagnose Brain Tumors
Craig Horbinski, MD, PhD

11:10 AM

Update on Radiation Management of Lower Grade Glioma
Sujay Vora, MD

11:50 AM

Biology and Medical Management of Low Grade Glioma in Adults
Susan Chang, MD

12:20 PM

Panel Discussion

12:30 PM

LUNCH BREAK

Radiology/Pathology/Clinical Trials
Moderators:  Mahua Dey, MD and Joseph Bovi, MD

1:30 PM

RANO Criteria: Clinical Trial Endpoints and Response Assessment
Patrick Wen, MD

2:10 PM

Updates on Surgical Management of Low Grade Glioma
Mitchel Berger, MD

2:40 PM

Clinical Trial Designs: Brain Tumor Studies
Mark Gilbert, MD

3:10 PM

Evaluation of Glioma Treatment Response using Perfusion MRI
Kathleen Schmainda, PhD

3:40 PM

If There Were Something Seriously Wrong: A Diagnosis Story
Adam Hayden

4:10 PM

Neurocognitive Effects of Glioma Treatment
Alissa Butts, PhD

4:40 PM

Panel Discussion

5:00 PM

ADJOURN

THIS IS A VIRTUAL CONFERENCE (CENTRAL DAYLIGHT TIME). PLEASE SEE THE PROGRAM FOR FURTHER INFORMATION.

A LINK TO THE WEBINAR WILL BE SENT TO PARTICIPANTS PRIOR TO THE ACTIVITY START DATE.

Course Directors

Mahua Dey, MD; Assistant Professor of Neurological Surgery, University of Wisconsin School of Medicine and Public Health

Joseph Bovi, MD; MCW, Professor of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI

Visiting Faculty

Mitchel Berger, MD; Director of Brain Tumor Center and Professor of Neurological Surgery, University of California San Francisco

Alissa Butts, PhD; Assistant Professor of Neurology, Medical College of Wisconsin

Susan Chang, MD; Professor and Vice Chair of Neurological Surgery, Weill Institute for Neurosciences University of California San Francisco

E. Antonio Chiocca, MD, PhD; Chair of Department of Neurosurgery, Harvard Medical School

Mark Gilbert, MD; Senior Investigator, Neuro-Oncology Branch of Intramural Research Program, National Institutes of Health

Adam Hayden; Research Roundtable Steering Committee, National Brain Tumor Society; Consumer Reviewer, Peer Reviewed Cancer Research Program; Scientist-Survivor Program participant American Association for Cancer Research

Craig Horbinski, MD, PhD; Director of Neuropathology and Professor of Pathology and Neurological Surgery, Feinberg School of Medicine Northwestern University

Minesh P. Mehta, MD; Deputy Director and Chief of Radiation Oncology, Miami Cancer Institute at Baptist Health South Florida

Kathleen Schmainda, PhD; Professor of Biophysics, Medical College of Wisconsin

Roger Stupp, MD; Professor of Neurological Surgery, Medicine, and Neurology; Feinberg School of Medicine Northwestern University

Sujay Vora, MD; Associate Professor of Radiation Oncology, Mayo Clinic

Patrick Wen, MD; Professor of Neurology, Harvard Medical School

University of Wisconsin Faculty

Robert Dempsey, MD; Manucher Javid Professor and Chairman of Neurological Surgery, University of Wisconsin School of Medicine and Public Health

Mahua Dey, MD; Director of Surgical Neuro-oncology, Assistant Professor of Neurological Surgery, University of Wisconsin School of Medicine and Public Health

Planning Committee

Joseph Bovi, MD; MCW, Professor of Radiation Oncology and Neurosurgery, Medical College of Wisconsin, Milwaukee, WI

Mahua Dey, MD; Assistant Professor of Neurological Surgery, University of Wisconsin School of Medicine and Public Health

Jessica Leiberg, DNP; Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health

Terese Bailey, BS; Senior Outreach Specialist, Office of Continuing Development, University of Wisconsin–Madison ICEP


POLICY ON DISCLOSURE

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the  speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE).  In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.

For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.

Name of Individual

Individual’s Role in Activity

Name of Commercial Interest &
Nature of Relationship

Discussion of
Unlabeled/Unapproved
Uses of Drugs/Devices
in Presentation?

Terese Bailey, BS

Planner

No relevant relationships with ineligible companies to disclose

No

Mitchel Berger, MD

Speaker

No relevant relationships with ineligible companies to discloseNo
Joseph Bovi, MD

Co-Director & Moderator

No relevant relationships with ineligible companies to discloseNo
Alissa Butts, PhD

Speaker

No relevant relationships with ineligible companies to discloseNo
Susan Chang, MD

Speaker

Agios Pharmaceuticals, Inc. (Grant)No
E. Antonio Chiocca, MD, PhD

Speaker

DNAtrix (Contractor), Voyager (Contractor), Immunomic therapeutics (Contractor), Advantagene Inc - Oncolytic Viruses (Patent), InSightec,Inc (Contractor), GlaxoSmithKline, LLC. (Contractor), Advantagene Inc (Contractor), Seneca Therapeutics (Stock Option), long noncoding RNAs and microRNAs (Patent), DNAtrix (Contractor)Yes

Robert Dempsey, MD

Speaker

No relevant relationships with ineligible companies to discloseNo

Mahua Dey, MD

Course Co-Director & Moderator

No relevant relationships with ineligible companies to discloseNo
Mark Gilbert, MD

Speaker

No relevant relationships with ineligible companies to discloseNo
Adam Hayden

Speaker

Medecision, Inc. (Travel); Briljent, LLC (Employment); National Brain Tumor Society (Contractor)No
Craig Horbinski, MD, PhD

Speaker

No relevant relationships with ineligible companies to discloseNo

Jessica Leiberg, DNP

Planner

Marquette University (Employment),
St. Francis Xavier University (Employment)

 
Minesh P. Mehta, MD

Speaker

Mevion Medical Systems, Inc. (Contractor); Sapience (Contractor); Zap Surgical (Contractor); Karyopharm Therapeutics (Contractor); Oncoceutics (Stock Option; BOD)No
Kathleen Schmainda, PhD

Speaker

IQ-Al Ltd, Imaging Biometrics LLC (Stock); IQ-Al Ltd, Imaging Biometrics LLC (Spouse/Partner: Employment)

No

Roger Stupp, MD

Speaker

Triact (Contractor); CarThera (Grant); GT Medical Technologies (Contractor); CranioVation (Contractor); Hemispherian AS (Contractor); Northwest Biotherapeutics (Contractor); InSightec, Inc. (Contractor); Celularity (Contractor); DNAtrix Inc. (Contractor)Yes
Sujay Vora, MDSpeakerNo relevant relationships with ineligible companies to discloseNo
Patrick Wen, MDSpeakerGenentech/Roche (Contractor), CNS Pharmaceuticals (Contractor), Boston Pharmaceuticals (Contractor), Immunomic Therapeutics (Contractor), MedicNova (Contractor), Vascular Biogenics (Contractor), Karyopharm Therapeutics (Contractor), Voyager (Contractor), Celgene (Contractor), Bayer (Contractor), Kazia (Contractor), VBI Vaccines (Contractor), Agios Pharmaceuticals, Inc. (Contractor), Merck (Contractor), AstraZeneca (Contractor), Astra Zeneca/Medimmune (Contractor), Novartis (Contractor), QED Therapeutics (Contractor), Imvax (Contractor), Oncocentiucs (Contractor), Elevate Bio (Contractor), Eli Lilly (Contractor), Nuvation Bio (Contractor), Boston Pharmaceuticals (Contractor)No

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on, patients.

The ACCME does not consider providers of clinical services directly to patients to be commercial interests.

 

Discloser List CME Internal Report

Accreditation Statement

Jointly Accredited Provider Logo

In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and the Medical College of Wisconsin. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

CREDIT DESIGNATION STATEMENTS

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 7.75 ANCC contact hours.

The University of Wisconsin–Madison School of Nursing is Iowa Board of Nursing provider 350. Iowa Board of Nursing accepts ANCC contact hours for nursing continuing education requirements.

Continuing Education Units (CEUs)

The University of Wisconsin–Madison, as a member of the University Professional Continuing Education Association (UPCEA), authorizes this program for 0.775 continuing education units (CEUs) or 7.75 hours.

Available Credit

  • 7.75 AMA PRA Category 1 Credit
  • 7.75 ANCC Contact Hours
  • 7.75 University of Wisconsin–Madison Continuing Education Hours
    • 7.75 Approved for AMA PRA Category 1 Credit™

Price

Cost:
$50.00
Please login or register to take this course.

Registration Fees

$50.00 MD/DO
$25.00 Other healthcare providers
$0.00   Trainees, including fellows, residents and students

Syllabus Materials

Syllabus materials will be posted on this site.  Materials will be available to registered participants 48 hours (March 18) prior to the event.

CANCELLATION AND REFUND POLICY

Requests for cancellation must be submitted in writing to help@icep.wisc.edu. Cancellation requests received at least 96 hours prior to the conference will allow a full refund except for the $10 nonrefundable processing fee. No refunds will be made for cancellations received less than 96 hours prior to the activity start date.

PROGRAM CHANGES

Emergency situations occasionally occur and may necessitate topic or speaker changes. The University of Wisconsin School of Medicine and Public Health and the University of Wisconsin–Madison ICEP reserve the right to alter or substitute a topic or speaker without prior notification.

For Further Information

For conference information or details, please contact Mahua Dey, MD by emailing edlund@neurosurgery.wisc.edu